Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (3627)	1/16/1998 1:47:00 AM
From: JOHN W.	Read Replies (1) of 6136

Morgan Stanley (1/13/97): "Based on this quartersperformance, and our strong belief that Viracept will remain the domuinant HIV protease inhibitor in a growing market, we have raised our revenue and EPS forecast. We are raising fiscal 1998 Viracept revenues to $355 million from $345 million, fiscal 1999 revenues to $447 million from $431 million and fiscal 2000 revenues to $512 million from $504 million. Our EPS estimates increase to $0.91 from $0.86 and to $1.62 from $1.57 for FYE 1998 and 1999, respectively. We conservatively maintain our $2.14 EPS estimate for 2000."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next